A phase III multicenter randomized clinical trial comparing gemcitabine alone or in combination with capecitabine for the treatment of patients with advanced pancreatic cancer

Trial Profile

A phase III multicenter randomized clinical trial comparing gemcitabine alone or in combination with capecitabine for the treatment of patients with advanced pancreatic cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2016

At a glance

  • Drugs Gemcitabine (Primary) ; Capecitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Nov 2012 United Kingdom Clinical Research Network reports accrual to date as 104%.
    • 29 Nov 2012 New source identified and integrated (United Kingdom Clinical Research Network: 701).
    • 26 Nov 2009 Actual end date (18 Jan 2005) added as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top